Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells

Author(s): Diego De Miguel, Ana Gallego-Lleyda, José M. Ayuso, Aleksandra Pawlak, Blanca Conde, Ignacio Ochoa, Luis J. Fernández, Alberto Anel, Luis Martinez-Lostao.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 11 , Issue 2 , 2016

Submit Manuscript
Submit Proposal

Abstract:

Background: Apo2-ligand/TRAIL, a member of the TNF cytokine superfamily capable of inducing apoptosis on tumor cells while sparing normal cells, is a promising anti-tumor agent. However, about 50% of human cancer are TRAIL resistant. Consequently, future TRAIL-based therapies will require the use of novel highly bioactive forms of TRAIL and/or the addition of sensitizing agents to TRAIL-induced apoptosis. Recently, we demonstrated that artificial lipid nanoparticles coated with bioactive TRAIL (LUV-TRAIL) greatly improved TRAIL activity and were able to induce apoptosis in chemoresistant hematological tumor cells.

Objective: In this study, we have tested LUV-TRAIL-pro-apoptotic potential in human breast cancer.

Method: Comparative analysis of cytotoxicity induced by sTRAIL and LUV-TRAIL was performed using several human breast tumor cell lines with different sensitivity to TRAIL. In vivo anti-tumor activity of LUV-TRAIL was also studied using a xeno-graft tumor model.

Results: LUV-TRAIL improved not only sTRAIL in vitro cytotoxicity in all breast tumor cell lines tested but also showed more anti-tumor activity than sTRAIL in an in vivo xeno-graft tumor model. On the other hand, the concomitant treatment of LUV-TRAIL with the sensitizing agent flavopiridol (FVP) induced a higher level of cell death in TRAIL-resistant cell lines. TRAIL-sensitization induced by FVP was mediated by DR5 up-regulation, and interestingly TRAIL-apoptotic signaling was completely shifted towards DR5 upon FVP treatment. LUV-TRAIL could especially take advantage of this DR5 up-regulation, while sTRAIL was not able.

Conclusion: To date, no special attention had been paid to this aspect of FVP-induced TRAIL-sensitization, may be because sTRAIL used were not able to take advantage of this DR5 up-regulation. Hence, LUV-TRAIL could be a better choice than sTRAIL to be used in combination with anti-tumor drugs inducing DR5 over-expression, since LUV-TRAIL is especially effective activating this death-receptor.

Keywords: Breast cancer, DR5, flavopiridol, immunotherapy, lipid nanoparticles, TRAIL.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 11
ISSUE: 2
Year: 2016
Page: [197 - 214]
Pages: 18
DOI: 10.2174/1574892811666160229121544
Price: $58

Article Metrics

PDF: 27
HTML: 1
EPUB: 1
PRC: 1